Syndax Pharmaceuticals Inc (SNDX): Total Assets
$529.71M
As of 2025-12-31
$703.65M
As of 2026-06-30
+2.1%
3-year compound annual growth
+12.0%
5-year compound annual growth
+19.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $529.71M | -26.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $724.82M | +18.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $612.88M | +23.3% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $497.24M | +10.6% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $449.66M | +49.6% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $300.61M | +373.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $63.52M | -24.3% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $83.94M | -38.8% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $137.19M | +25.8% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $109.01M | +21.3% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $89.90M | n/a | 2017-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $259.15M | -31.5% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $418.43M | +54.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $255.88M | +9.7% |
Compare SNDX, PHAT, CYRX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗